Urinary tract infections: cystitis, pyelonephritis, and field treatment

Urinary tract infections are among the most common bacterial infections managed in primary care — and among the most mismanaged in austere settings. Uncomplicated cystitis is usually easy to treat empirically with a short antibiotic course; most people recover fully within days. The danger comes from two failure modes: missing the transition to pyelonephritis (kidney infection), which carries a significant risk of sepsis, and treating incorrectly — wrong drug, wrong duration, or unnecessary antibiotics for a mimic — which drives resistance and leaves the real problem untreated.

Educational use only

This page provides general educational information for emergency preparedness scenarios when professional medical care is unavailable. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider. Use this information at your own risk.

Before you start - Skills: Locate the costovertebral angle (CVA) on the back — between the bottom of the 12th rib and the lateral spine — and perform CVA percussion: strike your own hand firmly with a closed fist while it rests flat over the patient's CVA. No clinical training required for symptom assessment; basic anatomy orientation needed for CVA exam. - Materials: Digital thermometer. Stockpile covering at minimum: nitrofurantoin 100 mg capsules, trimethoprim-sulfamethoxazole 160/800 mg (DS) tablets, cephalexin 500 mg capsules, ciprofloxacin 500 mg tablets — see medical stockpiling and long-term medication strategy for procurement and storage. - Antibiotic thresholds: First-line empiric antibiotic selection per IDSA 2010 uncomplicated UTI guideline (Gupta et al., Clinical Infectious Diseases 52:e103–e120, 2010); pyelonephritis per IDSA 2010 same document. - Pregnancy thresholds: ACOG Clinical Consensus on UTIs in Pregnancy (2023) — all bacteriuria in pregnancy is treated, including asymptomatic; nitrofurantoin contraindicated at ≥38 weeks gestation due to risk of hemolytic anemia from immature neonatal erythrocyte enzyme systems. - Pediatric thresholds: Any infant ≤2 months with fever ≥100.4°F (38°C) must be evaluated in an emergency setting — rule out sepsis, no exceptions, per AAP.

Action block

Do this first: Measure the patient's temperature and check for flank pain — these two findings separate cystitis (bladder, treat outpatient) from pyelonephritis (kidney, higher stakes) before any antibiotic is chosen (active time: 3 minutes). Time required: Active: 3 minutes for initial triage; antibiotic course is 3–7 days depending on drug and diagnosis; reassessment at 48 hours. Cost range: Inexpensive for generic nitrofurantoin, TMP-SMX, or cephalexin; affordable for a pre-stocked supply of cephalexin and ciprofloxacin adequate for a household. Skill level: Beginner for symptom recognition and first-line cystitis treatment; intermediate for pyelonephritis management and pregnancy precautions; advanced for urosepsis recognition and management. Tools and supplies: Tools: digital thermometer. Supplies: stockpiled nitrofurantoin 100 mg, TMP-SMX 160/800 mg DS, cephalexin 500 mg, ciprofloxacin 500 mg, and ideally ceftriaxone 1 g IM for severe pyelonephritis per stockpiling. Safety warnings: See Pyelonephritis is a different emergency below — fever plus flank pain in a UTI patient changes the drug, the dose, the duration, and the evacuation threshold.

Recognizing UTI without a dipstick

Without a urinalysis or culture, diagnosis is clinical. The pattern of symptoms — which ones are present, which are absent — determines both what this is and what to do about it.

Symptom decision table

Syndrome	Key features	What is absent	Action
Cystitis (bladder UTI)	Burning on urination (dysuria), urgency, frequency, suprapubic tenderness, possibly pink or bloody urine	Fever, flank pain, nausea/vomiting	Start short-course antibiotic per table below
Pyelonephritis (kidney infection)	All cystitis symptoms PLUS fever ≥101°F (38.3°C), flank or back pain, nausea/vomiting, malaise	—	Longer antibiotic course, close monitoring, evacuation if severe
Asymptomatic bacteriuria	Positive culture but zero symptoms	All symptoms	Treat ONLY in pregnancy or pre-urologic procedure — not in non-pregnant adults (per IDSA)
Urethritis	Dysuria only, no frequency, no urgency, possible discharge	Suprapubic tenderness, urgency	Consider STI (gonorrhea, chlamydia) — needs different treatment
Vaginitis	Itching, discharge, odor	Urgency, frequency, flank pain	Not a UTI; treat underlying cause (yeast, bacterial vaginosis, trichomonas)
Interstitial cystitis	Chronic pelvic pain, frequency — no acute onset	Fever, systemic symptoms	Not infectious; antibiotics are the wrong treatment
Kidney stone	Severe colicky flank pain, hematuria, pain radiates to groin	Fever (unless stone + infection present, which is surgical emergency)	Hydration; if fever + stone = emergent

Sources: IDSA 2010 Uncomplicated UTI Guideline — Gupta et al., CID 52:e103 (Tier 1); IDSA 2025 Complicated UTI Update (Tier 1).

Cystitis is most common in adult women

The anatomy is the reason. The female urethra is approximately 1.5 inches (3.8 cm) long, compared to 8 inches (20 cm) in men. Bacteria from the perianal region reach the bladder with far less distance to travel. This explains why UTIs are 50 times more common in women than in healthy young men. A healthy adult man with symptoms of cystitis should prompt consideration of a complicating factor — prostatitis, sexually transmitted infection, or structural abnormality — and warrants more careful evaluation even when antibiotics are indicated.

How to check CVA tenderness

Costovertebral angle (CVA) tenderness is the key bedside sign separating bladder infection from kidney infection.

Have the patient sit upright, facing away from you.
Locate the CVA: the angle formed by the bottom of the 12th rib and the lateral edge of the spine on each side — roughly at the level of the mid-back, above the waist.
Place your non-dominant hand flat over the right CVA.
Strike the back of your non-dominant hand firmly once with the closed fist of your dominant hand — enough force to produce a thud, not a tap.
Ask the patient: "Does that hurt?" Positive result is sudden, sharp pain that is distinctly different from the muscle soreness of being struck.
Repeat on the left side.
A positive CVA tenderness sign suggests kidney involvement and shifts the working diagnosis toward pyelonephritis.

Field note

CVA tenderness can be absent even in confirmed pyelonephritis, particularly early in the course or in immunocompromised patients. Do not exclude kidney infection on the basis of absent CVA tenderness if fever, nausea, and flank discomfort are all present. The clinical pattern counts more than any single finding.

Empiric antibiotic selection for uncomplicated cystitis

"Uncomplicated" means a bladder infection in a non-pregnant adult woman without structural abnormality, no immunocompromise, and no fever. The goal of drug selection is the narrowest effective antibiotic with the lowest collateral impact on gut flora. Fluoroquinolones (ciprofloxacin, levofloxacin) are explicitly not recommended as first-line for uncomplicated cystitis per IDSA — they carry an FDA black-box warning for tendonitis, tendon rupture, peripheral neuropathy, and CNS effects, and they should be reserved for pyelonephritis and complicated infections where their tissue penetration matters.

Antibiotic	Dose and duration	Notes	Avoid when
Nitrofurantoin macrocrystals	100 mg twice daily × 5 days	First-line per IDSA 2010. Minimal resistance, low collateral damage to gut flora.	Creatinine clearance <45 mL/min; pregnancy at term (≥38 weeks per ACOG 2023; many clinicians stop earlier ≥36 weeks for safety margin) due to neonatal hemolytic anemia risk; G6PD deficiency
TMP-SMX (trimethoprim-sulfamethoxazole DS)	160/800 mg twice daily × 3 days	Use only if local E. coli resistance is <20%. In grid-down settings without susceptibility data, this threshold is unknown — use nitrofurantoin instead	First trimester of pregnancy (folate antagonism risk); near term ≥36 weeks (kernicterus risk in neonate); sulfa allergy
Fosfomycin	3 g single dose in water	One-and-done convenience if available; effective, moderate cost	Severe kidney disease
Cephalexin	500 mg four times daily × 5–7 days	Not first-line but useful when nitrofurantoin is unavailable or contraindicated; good pregnancy option	Serious penicillin/cephalosporin allergy
Amoxicillin-clavulanate	500/125 mg twice daily × 5–7 days	Alternative; better than amoxicillin alone due to beta-lactamase coverage	Amoxicillin allergy
Ciprofloxacin, levofloxacin	—	Do not use as first-line for uncomplicated cystitis. Reserve for pyelonephritis. FDA black-box for musculoskeletal and CNS adverse effects.	Save for pyelonephritis and complicated UTI
Ampicillin, amoxicillin alone	—	High resistance rates among uropathogens. Do not use empirically	—

Always take the full course. Nitrofurantoin produces symptomatic relief within 24–48 hours. Stopping at day 2 because "it feels better" leaves viable bacteria in the bladder and selects for resistance. Complete all 5 days regardless of symptom improvement.

Reassess at 48 hours. Symptoms should be clearly improving. No improvement or worsening = possible treatment failure, resistant organism, or wrong diagnosis (pyelonephritis, non-infectious mimic). Reconsider the antibiotic and the diagnosis.

Pyelonephritis is a different emergency

Cystitis and pyelonephritis are not the same illness at different severities — they are different clinical problems requiring different antibiotics, different durations, different monitoring, and different evacuation thresholds.

Do not treat pyelonephritis with the cystitis regimen. Nitrofurantoin does not achieve therapeutic tissue concentrations in the kidney. Using it for pyelonephritis is not just inadequate — it will produce apparent symptom improvement (analgesic effect) while the kidney infection progresses. This is one of the most dangerous management errors on this page.

Pyelonephritis: when antibiotics and escalation are both needed

Pyelonephritis requires an antibiotic that achieves adequate tissue concentrations in the kidney — not just in the urine. The fluoroquinolones (ciprofloxacin, levofloxacin) and IV ceftriaxone meet this requirement; nitrofurantoin does not.

Outpatient management (mild pyelonephritis)

Outpatient management is appropriate when the patient:

Is tolerating oral fluids and medications
Has no signs of sepsis (see qSOFA section below)
Has no fever above 103°F (39.4°C)
Is not pregnant
Is not immunocompromised

Antibiotic selection for outpatient pyelonephritis:

Ciprofloxacin 500 mg twice daily × 7 days — first-line per IDSA 2010 for pyelonephritis when fluoroquinolone resistance is not suspected.
Levofloxacin 750 mg once daily × 5 days — equivalent alternative with once-daily dosing per IDSA.
Avoid fluoroquinolones if the patient had any fluoroquinolone exposure in the past 12 months — per 2025 IDSA complicated UTI update, prior fluoroquinolone exposure predicts resistance.
If fluoroquinolones must be avoided: TMP-SMX 160/800 mg twice daily × 14 days — only if organism is likely susceptible (known susceptibility or low-resistance area). Otherwise, escalate to ceftriaxone and hospital care.
Initial single parenteral dose: Per IDSA 2010, when fluoroquinolone resistance is suspected to exceed 10% in the community, give an initial 1 g dose of ceftriaxone (IV per IDSA; IM is the practical field route when IV access is unavailable) before starting oral antibiotics. This "bridging" dose provides immediate tissue concentrations while oral dosing ramps up.

Supportive care:

Anti-emetic if nausea is preventing oral intake
Aggressive oral hydration — minimum 2 liters (about 2 quarts) per day
Acetaminophen 650–1,000 mg every 6–8 hours for fever and pain
Record temperature, mental status, and urine output every 4–6 hours

24–48 hour re-evaluation: A patient with pyelonephritis treated outpatient must be reassessed at 24 hours. Failure to improve — persistent fever, worsening nausea, inability to tolerate oral intake, or any new systemic symptoms — means outpatient management has failed and hospital-level care is needed. Do not extend the oral course while the patient deteriorates.

Severe pyelonephritis — inpatient or evacuation threshold

Escalate to hospital-level care (or evacuate if no hospital is accessible) when any of the following are present:

Fever ≥103°F (39.4°C) that is not responding to antipyretics
Vomiting that prevents oral antibiotic intake
Hypotension or any sign of sepsis
qSOFA score ≥2 (see next section)
Pregnancy
Immunocompromised patient
Known or suspected obstructing kidney stone (see note below)

In an austere setting when evacuation is impossible:

Start ceftriaxone 1 g IM once daily if available — this is the most useful parenteral antibiotic for severe pyelonephritis when oral route is unreliable.
Provide aggressive oral rehydration solution (ORS) — see dehydration for the WHO formula and dosing.
Reassess qSOFA every 4–6 hours.
If the patient deteriorates to septic shock (hypotension not responding to fluids, altered mental status), prepare family for a potentially fatal outcome without hospital intervention. Prioritize comfort and evacuation efforts simultaneously.

Obstructed stone plus infection = surgical emergency

A patient with pyelonephritis symptoms AND decreased urine output AND severe colicky flank pain likely has an obstructed infected kidney stone. This is a urological surgical emergency — the infected urine cannot drain past the obstruction, and the infection accelerates toward perinephric abscess and overwhelming sepsis. No antibiotic alone can resolve this. Evacuation is non-negotiable. Do not observe; do not extend treatment. Evacuate.

Sources: IDSA 2010 — Gupta et al., CID 52:e103 (Tier 1); IDSA 2025 Complicated UTI Update (Tier 1); Medscape Acute Pyelonephritis Treatment (Tier 2).

Urosepsis: the qSOFA threshold

Any patient presenting with UTI symptoms and systemic features — confusion, rapid breathing, low blood pressure — needs a qSOFA assessment before antibiotic selection, not after.

qSOFA criteria (one point each, per Sepsis-3):

Altered mental status (confusion, disorientation, unusual behavior)
Respiratory rate ≥22 breaths per minute
Systolic blood pressure ≤100 mm Hg

Score ≥2 = urosepsis emergency. Mortality from septic shock in urosepsis exceeds 30% even with hospital treatment. Without IV antibiotics and fluid resuscitation, outcome is grave.

In austere settings with a qSOFA ≥2 UTI patient:

Start the broadest available antibiotic immediately — if oral route is intact, ciprofloxacin 500 mg now. If ceftriaxone IM is available, use it instead or alongside oral antibiotics.
Aggressive oral rehydration if the patient can swallow — see dehydration. Oral route is inadequate for septic shock; if hypotension is present, IV fluids are needed.
Evacuate simultaneously with treatment — do not delay antibiotic for transport, do not delay transport for antibiotic response.
Reassess every 2 hours. Mental status is the most sensitive clinical indicator of trajectory.
If evacuation is impossible and the patient is deteriorating despite antibiotics and fluids, the prognosis is poor. Comfort measures are appropriate and compassionate — see infection for the full sepsis protocol and the no-escalation framework.

Cross-reference: the infection and sepsis page contains the full sepsis progression timeline, SIRS criteria, and comfort-care framework for when hospital-level care is definitively unavailable.

Pregnancy: every UTI matters

Pregnancy alters the physiology and the stakes simultaneously. Progesterone relaxes smooth muscle — including the ureters — which slows urine flow and allows bacteria to ascend more easily to the kidney. At the same time, untreated UTI in pregnancy is linked to preterm labor, low birth weight, and sepsis. This is why ACOG recommends treating all bacteriuria in pregnancy, including asymptomatic bacteriuria.

Asymptomatic bacteriuria: Without symptoms but with confirmed bacteria in urine, the risk of progression to pyelonephritis in untreated pregnant patients is 24–37%. In non-pregnant healthy adults, asymptomatic bacteriuria is not treated — the risk-benefit is unfavorable. In pregnancy, treat always.

Empiric antibiotic selection in pregnancy (cystitis or asymptomatic bacteriuria):

Antibiotic	Dose and duration	Safety in pregnancy
Cephalexin (first-line empiric)	500 mg four times daily × 7 days	Safe throughout pregnancy; preferred empiric choice per ACOG 2023
Amoxicillin-clavulanate	500/125 mg three times daily × 7 days	Safe in pregnancy; broader coverage than cephalexin alone
Nitrofurantoin	100 mg twice daily × 5 days	Reasonable in first and second trimesters; CONTRAINDICATED at ≥36–38 weeks due to risk of neonatal hemolytic anemia from immature G6PD enzyme system; avoid in patients with known G6PD deficiency
TMP-SMX	—	AVOID in first trimester (folate antagonist — neural tube defect risk); AVOID near term ≥36 weeks (kernicterus risk). Use only in second trimester if other options not available
Fluoroquinolones (ciprofloxacin, levofloxacin)	—	AVOID in pregnancy — associated with fetal cartilage toxicity in animal studies; use only when no alternative exists and maternal life is at risk
Tetracyclines (doxycycline)	—	AVOID — causes fetal tooth and bone staining; not appropriate for UTI in pregnancy under any circumstances

Duration: Pregnant women receive longer courses (7 days minimum) than non-pregnant women (3–5 days) for the same reason — more thorough eradication reduces recurrence risk.

Suppressive therapy after pyelonephritis in pregnancy: Recurrent pyelonephritis occurs in up to 25% of pregnant women before delivery after an initial episode. Daily suppressive therapy — nitrofurantoin 100 mg nightly (until 36 weeks) or cephalexin 250–500 mg nightly — reduces this risk through delivery and 4–6 weeks postpartum.

Pyelonephritis in pregnancy = hospital admission, no exceptions. The risks of undertreated pyelonephritis in pregnancy include sepsis, preterm labor, acute respiratory distress syndrome (ARDS), and fetal loss. In an austere setting, evacuate. If evacuation is impossible, start ceftriaxone 1 g IM once daily and IV-equivalent oral hydration, monitor closely, and continue evacuation efforts. Cross-reference the childbirth page for situational awareness on preterm labor signs.

Sources: ACOG Clinical Consensus on UTIs in Pregnancy, 2023 (Tier 1); IDSA 2010 — Gupta et al., CID 52:e103 (Tier 1).

Pediatric UTI

UTI in children often presents differently than in adults — and the stakes for delayed recognition are higher, because untreated UTI in infants can cause permanent kidney scarring (renal cortical defects) and hypertension.

Red flags by age

Infants ≤2 months with any fever ≥100.4°F (38°C): Do not attempt to diagnose or treat UTI in this group in the field. Fever in a neonate or young infant may represent bacteremia, UTI with bacteremia, or meningitis — all indistinguishable without laboratory evaluation. Evacuate immediately per AAP; this population cannot be safely managed without blood cultures and hospital monitoring.

Infants 2–24 months with unexplained fever: UTI is the most common bacterial infection in this age group. Signs are non-specific: fever without obvious source, irritability, vomiting, poor feeding, and occasionally jaundice in the newborn period. There is no burning sensation to report. A febrile infant in this age range without a clear viral cause needs urine evaluation — in austere settings, treat empirically if evacuation is unavailable and UTI is the working diagnosis.

Children over 2 years: More likely to report symptoms similar to adults — dysuria, frequency, urgency — allowing a more confident clinical diagnosis.

Pediatric antibiotic selection

Age and presentation	Antibiotic	Dose	Duration
2–6 months, febrile UTI	Evacuate; if impossible — cephalexin	50 mg/kg/day divided four times daily (max 4 g/day)	7–14 days
>6 months, cystitis	Cephalexin (first-line)	25–50 mg/kg/day divided 2–4 times daily	7–10 days
>6 months, febrile UTI/pyelonephritis	Cephalexin (first-line)	50–100 mg/kg/day divided 3–4 times daily	7–14 days
>6 months, alternative	Amoxicillin-clavulanate	25–45 mg/kg/day divided twice daily	7–10 days
>2 months, TMP-SMX option	TMP-SMX	8 mg/kg/day TMP component divided twice daily	5–7 days
All ages	Avoid fluoroquinolones	—	Fluoroquinolones are not recommended in patients under 18 unless no safe alternative exists — cartilage toxicity risk in growing joints

Recurrent pediatric UTI: Two or more febrile UTIs in a child warrants evaluation for vesicoureteral reflux (VUR) or anatomical abnormality by a pediatric nephrologist or urologist. In austere settings, document each episode carefully and prioritize this evaluation when access to care is restored.

Recurrent UTI in adult women: prevention strategies

Recurrent UTI is defined as three or more episodes in 12 months, or two or more in six months. This is common — approximately 20–30% of women with a first UTI will have recurrence. Prevention strategies reduce frequency without eliminating the need for occasional treatment.

Behavioral measures (evidence-informed, low-cost):

Post-coital voiding: Urinate within 15–30 minutes after intercourse. The mechanical flushing of the urethra removes bacteria introduced during sexual activity. This is one of the most consistently supported behavioral interventions.
Adequate fluid intake: When daily water intake is below 1.5 liters (about 50 oz), increasing to 2–2.5 liters (64–84 oz) per day reduces recurrence. This is not about "flushing out" an active infection — it is a prevention measure.
Wiping front to back: Reduces perianal-to-periurethral bacterial contamination. Basic hygiene measure with plausible mechanism and no downside.
Avoid vaginal douches, harsh soaps, bubble baths, and scented products near the urethral opening — these disrupt the normal vaginal flora that provides some protection against uropathogens.

Cranberry: Cranberry extract (proanthocyanidins, PAC ≥36 mg/day) may reduce UTI recurrence by preventing bacterial adhesion to the bladder epithelium. The AUA/CUA/SUFU 2022 guideline offers it as an option. Effect size is modest. Cranberry juice is less effective than concentrated extract due to sugar content. Cranberry is a prevention adjunct, not a treatment.

Topical estrogen for postmenopausal women: Declining estrogen after menopause reduces lactobacillus-dominant vaginal flora, raising susceptibility to UTI. Topical vaginal estrogen (low-dose cream or suppository) restores protective flora and significantly reduces recurrence. This requires a prescription and is not field-accessible in most austere settings — but postmenopausal women with recurrent UTI should know this option exists.

Antibiotic prophylaxis — when behavioral measures fail:

Continuous daily prophylaxis: Nitrofurantoin 50–100 mg nightly or TMP-SMX 40/200 mg (half-strength tablet) nightly. Taken for 6–12 months. Effective but carries long-term side-effect profile — nitrofurantoin's rare pulmonary and hepatic toxicity (reported at 0.001% and 0.0003% respectively) and the resistance-selection pressure of any prolonged antibiotic use.
Post-coital prophylaxis: Single dose of nitrofurantoin 100 mg or TMP-SMX 40/200 mg taken within 2 hours of intercourse. Only relevant when recurrence is clearly coitus-associated.

In any prolonged scenario without pharmacy access, continuous prophylaxis is impractical. Focus on behavioral prevention and reserve antibiotics for symptomatic episodes.

Sources: AUA/CUA/SUFU Recurrent UTI Guideline 2022 (updated 2025) (Tier 1); IDSA 2010 — Gupta et al., CID 52:e103 (Tier 1).

Hydration, cranberry, and what actually works

The "drink more water to flush it out" advice is not wrong, but it is frequently misframed. Getting the nuance right prevents people from waiting 48 hours on water before starting an antibiotic — a delay that allows cystitis to progress toward pyelonephritis.

What increased fluid intake does: It increases urine flow, which may modestly reduce bacterial load in the bladder. As a prevention measure over weeks, consistent hydration below 1.5 L/day is a risk factor for UTI — increasing to 2+ L/day reduces that risk. As a treatment for active infection, it is not an antibiotic. It provides symptomatic relief by diluting the urine (less burning) but does not eradicate bacteria.

What cranberry juice does: The PAC compounds in cranberry reduce bacterial adhesion. Effect is prevention, not treatment. The sugar content of most commercial juice is a real downside — concentrated extract (PAC ≥36 mg daily) is a better option for prevention.

Urine alkalinizers (sodium citrate): Products like Ural reduce urine acidity, which relieves the burning discomfort of UTI. They are not antimicrobial. They provide symptomatic relief while the antibiotic does the actual work. This is appropriate — dysuria is genuinely miserable — but the alkalinizer is not treating the infection.

Acetaminophen and ibuprofen: Appropriate for pain and fever. Ibuprofen has some antimicrobial activity against E. coli in vitro, but this effect is clinically insignificant at standard doses. Do not use ibuprofen as a UTI treatment strategy.

Heating pad: Heat applied to the lower abdomen or back provides muscle relaxation and pain relief. No antimicrobial effect. Appropriate as symptomatic comfort.

Bottom line: Symptomatic relief while the antibiotic works is appropriate and humane. Symptomatic relief instead of an antibiotic, or delaying the antibiotic to "try the natural approach first," is dangerous. Start the antibiotic on the same day the diagnosis is made.

Common mistakes that get people killed or hospitalized

These are the failure patterns most likely to produce a bad outcome.

Missing pyelonephritis in someone who "just has a UTI." The patient has fever and low back pain but reports it as "regular UTI" because they've had UTIs before. The CVA exam is skipped. They're given a 3-day nitrofurantoin course. Nitrofurantoin does not reach therapeutic kidney concentrations. They worsen over the next 48 hours. This error kills people.
Treating asymptomatic bacteriuria in a non-pregnant adult. A urine culture shows bacteria; the patient has zero symptoms. An antibiotic is started. This drives resistance and C. difficile risk without benefit — IDSA explicitly recommends against treatment in non-pregnant adults. Reserve this practice for pregnancy and pre-urologic procedures only.
Prescribing a fluoroquinolone for uncomplicated cystitis. Ciprofloxacin works for simple cystitis but is overkill — it wastes a drug class that must be preserved for pyelonephritis and other serious infections. The FDA black-box risks (tendon rupture, neuropathy, CNS effects) are real and disproportionate for a self-limiting bladder infection.
Using nitrofurantoin in a pregnant patient at 36 weeks or beyond. Newborn G6PD enzyme systems are immature. Nitrofurantoin crosses the placenta and causes hemolytic anemia in susceptible neonates. Use cephalexin from 36 weeks through delivery.
Stopping antibiotics at day 2 because symptoms improved. The infection feels better because bacteria in the urine have been reduced — not eliminated. Stopping early selects for the most resistant organisms that survived the first days of treatment. Finish the full course.
Treating recurrent UTIs indefinitely with antibiotics without investigating cause. Three or more UTIs per year in a woman warrants consideration of anatomical evaluation, hormonal factors in postmenopausal women, and behavioral interventions. Chronic antibiotic cycling without investigation is poor medicine in any setting.
Missing urosepsis by skipping the qSOFA assessment. A patient with UTI symptoms who also has confusion and rapid breathing scores 2 on qSOFA. This is a sepsis emergency, not a UTI that needs a longer antibiotic course. The failure to apply qSOFA and recognize the systemic picture is a predictable, preventable death.
Missing an obstructed infected kidney stone. Flank pain + fever + decreased urine output = possible obstructed stone with infected urine above the obstruction. This scenario cannot resolve with antibiotics alone — drainage is required. The window for successful intervention is short.

Teach your family

Seven plain-language rules for household members who are not medically trained.

Burning when you pee plus needing to pee every few minutes = probably a bladder infection. Tell the adult in charge now, not tomorrow.
Bladder infection plus fever, back or side pain, or vomiting = kidney infection. This is more serious and needs a different medication and closer attention.
Drink water, yes — but also start the antibiotic from the medical kit. Water helps with the burning. Only the antibiotic treats the infection.
Pregnancy plus any urinary symptom = tell the adult immediately. Even if it seems mild. Even if there are no symptoms but a urine test shows bacteria. It always needs treatment.
Baby or young child with unexplained fever and no obvious cold or flu symptoms. UTI is a common cause. Do not assume it will pass. The baby cannot tell you it hurts to urinate.
Finish the full antibiotic course even if you feel better in 2 days. Stopping early allows the infection to come back, usually with a more resistant organism.
Not better in 48 hours, or getting worse? Wake the adult in charge. This may mean the wrong antibiotic, a kidney infection, or something else entirely.

The UTI framework connects directly to several other pages in the medical and preparedness foundations:

Pathogens and how they spread — the conceptual model for why different infections require different treatments
Wound infection and sepsis — the full qSOFA + SIRS sepsis protocol and comfort-care framework for when escalation is impossible
Dehydration and ORS — hydration protocol for febrile pyelonephritis; aggressive ORS for the patient who cannot keep up with losses
Childbirth — pyelonephritis in pregnancy can trigger preterm labor; understand the signs
Infant care — fever thresholds and the emergency-evaluation rule for neonates and young infants
Chronic conditions — diabetes, kidney disease, and immunosuppression all complicate UTI management
Medical stockpiling — nitrofurantoin, TMP-SMX, cephalexin, ciprofloxacin, and ceftriaxone quantities and shelf life
Long-term medication strategy — how to build and maintain an antibiotic supply during prolonged scenarios
Fever: recognition and management — fever triage, antipyretic dosing, and when fever itself demands escalation

Before you leave: antibiotic stockpile checklist

Nitrofurantoin 100 mg capsules: minimum 60 capsules (covers 5-day course for 6 adults)
TMP-SMX DS 160/800 mg tablets: minimum 36 tablets (3-day course for 6 adults); note local resistance concern in grid-down settings
Cephalexin 500 mg capsules: minimum 100 capsules (7-day QID course for 3-4 people; also covers pediatric UTI and pregnancy)
Ciprofloxacin 500 mg tablets: minimum 42 tablets (7-day course for 3 people; reserved for pyelonephritis)
Ceftriaxone 1 g vials + syringes for IM injection: if medically trained household member is present and capable of IM injection
Digital thermometer with extra batteries
Written antibiotic guide (this page or equivalent) in your printed medical binder
Every household member knows the 3 "escalate now" signs: fever + flank pain, confusion with UTI symptoms, decreased urine output with UTI symptoms

Sources and next steps

Last reviewed: 2026-05-22

Source hierarchy:

IDSA 2010 Uncomplicated Cystitis and Pyelonephritis Guideline — Gupta et al., Clinical Infectious Diseases 52:e103–e120 (Tier 1, primary guideline for empiric antibiotic selection)
IDSA 2025 Complicated UTI Guideline Update (Tier 1, fluoroquinolone exposure caveat and pyelonephritis updates)
ACOG Clinical Consensus on UTIs in Pregnancy, 2023 (Tier 1, pregnancy-specific management)
AAP Clinical Practice Guideline — UTI in Febrile Infants and Children 2–24 Months, Pediatrics 2011, reaffirmed 2016 (Tier 1, pediatric management)
Sepsis-3 — Singer et al., JAMA 2016;315(8):801-810 (Tier 1, qSOFA criteria and urosepsis recognition)
AUA/CUA/SUFU Recurrent UTI Guideline, 2022 (updated 2025) (Tier 1, recurrent UTI prevention strategies)

Legal/regional caveats: Antibiotic selection in this page reflects empiric guidance for settings without culture-and-sensitivity data. Where susceptibility testing is available, drug selection should be tailored to results. Prescribing antibiotics for human use requires a licensed clinician in most US jurisdictions — these guidelines are provided for preparedness education when licensed care is definitively unavailable. Fluoroquinolone black-box warning applies in all US jurisdictions and many international regulatory frameworks.

Safety stakes: life-safety topic — verify against current local/professional guidance before acting.

Next 3 links:

→ Wound infection and sepsis — qSOFA scoring, sepsis progression table, and the full protocol for when urosepsis exceeds field management capacity
→ Medical stockpiling — build the antibiotic supply that makes empiric treatment possible before you need it
→ Dehydration and oral rehydration — aggressive hydration protocol for febrile pyelonephritis, especially in patients who can't keep up with fluid losses (cross-Foundation: connects the medical treatment framework to the foundational hydration skill)